Growing evidence has linked insulin resistance with the development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Hyperinsulinemia is purported to enhance prostate smooth muscle tone and size and alter the transcription of genes involved in sex hormone metabolism (1). α-Adrenergic antagonists remain the cornerstone of care for treating LUTS. Tamsulosin was the first selective α-1a antagonist approved by the U.S. Food and Drug Administration in 1997. It has gained popularity among prescribers because it does not require dose titration and has marginal effects on blood pressure. Although side effects such as headache, dizziness, and abnormal ejaculation are well documented (2), less is known about what, if any, effects tamsulosin has on glucose homeostasis. Here, we present evidence supporting a probable association between tamsulosin and hyperglycemia.

A 68-year-old Caucasian man with a history of type 2 diabetes (diagnosed >10 years ago), BPH, erectile...

You do not currently have access to this content.